(AOF) – During the Society for Neuro-Oncology annual meeting, Noxxon Pharma presented the results of 9 chemotherapy-unresponsive patients (unmethylated MGMT promoter) participating in the proof of concept study on the inhibition of CXCL12 during and after radiotherapy in the treatment of glioblastoma. 8 of 9 patients (89%) treated with NOX-A12 showed reduction in tumor size (2 patients with objective responses – reduction> 50% – and 6 patients showed stabilization of the disease – reduction
These results compare favorably with historical results for patients in a matched cohort who received standard treatment, where only 1 in 13 (8%) patients experienced a reduction in tumor size with an objective response and where tumors of 12 patients progressed.
Likewise, the data from the analysis of the tissues of a patient under treatment with NOX-A12 show a significant reduction of the target of NOX-A12, CXCL12, on the blood vessels of the tumor, a significant decrease in proliferation. tumor cells and increased tumor infiltration of activated killer immune cells. Interestingly and very importantly, these benefits have been seen on all available tumor tissue and not just on small subsections.
©
AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written agreement of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.
